CryoPort

CYRX

Market cap $472M

Connected, Intelligent Condition Monitoring Assets that Safeguard Vital Life Science Materials Mark MVE's First Step in its Real-Time Integrated Systems Evolution NASHVILLE, Tenn. , Oct. 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences, today announced the unveiling of  MVE Biological Solutions ' ("MVE") integrated Condition Monitoring Solutions for its MVE SC 4/2 V and 4/3 V series dewars, both powered by Tec4Med, another Cryoport company.

The 55,000-Square-Foot Facility is the Latest Addition to Cryoport Systems' Global Supply Chain Center Network Designed to Support Complex Life Sciences Supply Chain Needs, Including Biologistics, BioServices and Future Cryopreservation Services Worldwide NASHVILLE, Tenn. , Oct. 1, 2025 /PRNewswire/ -- Cryoport, Inc.  (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced the launch of its newest, state-of-the art facility in Louvres, France, through its subsidiary, Cryoport Systems.

Cryoport (CYRX) Q2 Revenue Jumps 14%

Cryoport, Inc. (NASDAQ:CYRX ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Jerrell W. Shelton - Chairman, President & CEO Mark W.

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.33 per share a year ago.

Second quarter revenue increased 14% year-over-year to $45.5 million Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million Life Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestiture Company reaffirms full year 2025 revenue guidance of $165 to $172 million NASHVILLE, Tenn. , Aug. 5, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2025.

CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CryoPort, Inc. (CYRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CYRX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

NASHVILLE, Tenn. , July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after U.S. markets close.

New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology NASHVILLE, Tenn. , July 8, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' new vapor shippers, the SC 4/2V and SC 4/3V, offering medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceutical companies, and others dramatically improved safety and reliability for transporting and preserving sensitive biological materials at cryogenic temperatures.